Relax HCIT…
We aren’t members of that exclusive
Relax HCIT…
We aren’t members of that exclusive group of big Pharma yet… and I say yet.
It doesn’t mean we will not ever become members of the club. There apparently is some prerequisites we need to have in place first to achieve that membership. You’re guess is as good as mine on what we absolutely need but to me it revolves around money… and enough money to be able to jump through all the hoops.
When Frodo steered us to Brazil he gave our little company new life and that was a huge change for us to go international and not accepting the challenges of only the FDA . With being pushed off time after time with things they would like to see. Making it seem like it was a planned delay of our BLA for Duel HIV. I feel we will get more of a fair shake in Brazil or any other country than we do here at home in the USA.
If you look at the possibilities now and see how an approval works for us in Brazil and then the following countries with a domino effect… then we can judge our potential for revenue enough to maybe physically push our way into the US market with the much needed monies to do it right and quickly. Because I believe it only takes money and lots of it to get our trials done here in faster more realistic timelines.
Right now the majority of the patients are still trying big pharmas drugs instead of our and big Pharma pays more to get those patients. We have a hard time competing with other drugs not because we can’t save lives but because the money machine is beating us down. This is what I believe the biggest issue. Money/revenue is everything.
When we have more money to put towards trials and acquiring patients we will level the playing field. Then after a few approvals we won’t be that red headed step child any longer. ( I had those red highlights… so it’s personal) We will have come of age as a company and our approvals will come fast and often. How can we argue that we will not become a platform drug? Just have faith in our management for the direction they chose and see why it was the right choice considering the challenges we faced here.
Being an optimist is hard sometimes but seeing the potential for this company is very easy. Seeing the challenges is the problem with a moving target. I see so many shots on goal. Having 5 possible BTD’s in the next 6 months maybe 2 EUA’s just gives us the great odds of an approval or two before the end of 2022. Some could happen much sooner. I am a believer and will not let people like Craig poo poo on the possibilities with his negative perceptions and his attacks on our companies management. So we are doing just fine. We all have to realize that we have a champagne drug that we are trying to get across a finish line on a beer budget. It makes it tough. This is why we need to finance our 200 million shares so we can continue our path to success. It’s not only something we should do it’s something we have to do. The other options are far to risky. I am not a big fan of taking the risky way. Putting myself in the position of failure when we don’t have to. So voting the company line of everything they asked for is the best path. The one we need if we really want success.
When I use Frodo as a nickname for Nader I use it as a compliment. The protector our our precious Leronlimab… our precious…
file:///var/mobile/Library/SMS/Attachments/64/04/6FEB32D5-8821-4443-AA6C-A5DE15ED8A07/IMG_3422.JPG
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...
Continue Reading
Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....
Continue Reading
China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...
Continue Reading
Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...
Continue Reading
ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...
Continue Reading
Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...
Continue Reading
Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...
Continue Reading
Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...
Continue Reading
Top 5 Most Recently Viewed Articles
Bitcoin's Potential Surge Towards $100,000 Crypto analyst Trader Mayne has recently suggested that Bitcoin could be preparing for one final push toward the impressive milestone of $100,000. He notes, however, that the overall market cycle resembles a prolonged five-year super cycle, which may culminate in a significant downturn in the near future. Current Market...
Continue Reading
Geisinger Appoints Jason W. Mitchell, M.D. as CMO In a notable leadership transition, Geisinger has officially announced the appointment of Jason W. Mitchell, M.D. as its executive vice president and chief medical officer. This decision comes after an exhaustive search aimed at finding a leader with the vision and expertise to guide the organization into its next chapter....
Continue Reading
Insights Ahead of Euroseas's Earnings Report Euroseas (NASDAQ:ESEA) is gearing up to unveil its latest quarterly earnings, a moment that investors eagerly anticipate. This report holds substantial importance, as it can influence both investor sentiment and stock performance significantly. What Analysts Are Predicting Leading up to the earnings announcement, analysts...
Continue Reading
Atlantic Council and Antenna Group Unite for AEGGIS The Atlantic Council and Antenna Group have unveiled an exciting initiative known as the Alliance for Europe–Gulf Geopolitics & Investments Summit (AEGGIS). This summit is poised to play a pivotal role in strengthening the economic connections between European and Gulf nations. A Platform for Engagement and Dialogue...
Continue Reading
China Pharma's $5 Million Secured: A Strategic Move? Tough out there in the pharma jungle, isn't it? China Pharma Holdings, Inc. (NYSE American: CPHI) just wrapped up a neat $5 million direct offering. With each of their 2.5 million shares going for two bucks a pop, they're setting sails in a tumultuous sea. Now, why does this matter? Well, cash moshes in the pharma pit...
Continue Reading